At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
INCB054707 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
In Brief
A Phase 2 clinical trial evaluating INCB054707 and Placebo for Prurigo Nodularis. Completed, enrolled 146 participants across 49 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesCanada, Germany, Poland, Puerto Rico, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartNov 2021
Primary CompletionAug 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedSep 29, 2021
Enrollment StartNov 4, 2021
Primary CompletionAug 11, 2023
Study CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago
Interventions
INCB054707drug
Oral; Tablet
Placebodrug
Oral; Tablet